Somatic mutations in chromatin remodeler genes could modify the epigenomic landscape of CLL, but they are uncommon In this particular malignancy as compared to other lymphoid neoplasms. CHD2 aberrations and suit adequate to tolerate FCR therapy, should be very good candidates for your latter, wit